FDA Provides Full Approval to Praxbind (idarucizumab), Specific Reversal Agent for Pradaxa

Ridgefield, Conn., April 17, 2018 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has provided full approval for Praxbind (idarucizumab), the specific reversal agent for Pradaxa (dabigatran etexilate...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news